A Pharmacokinetic Study of the Combination Rifampicin Plus Trimethoprim in Man
Previous work in this laboratory (Kerry, Hamilton-Miller and Brumfitt 1975a,b) has shown that a combination of rifampicin (rif) and trimethoprim(tm) will inhibit virtually all common pathogenic bacteria. The combination has the added advantage of acting synergistically against several genera, notably streptococci and all species of proteus. Secondly, it suppresses the emergence of resistance to rifampicin. In view of these encouraging findings, we have now undertaken a pharmacokinetic study to determine whether rif and tm interfere with one another’s handling in man.